Nasal cavity carcinoma in situ

Summary

Nasal cavity carcinoma in situ (MONDO:0003784) is a cancer. A subtype of nasal cavity carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nasal cavity carcinoma in situ
Mondo ID	MONDO:0003784
DOID	DOID:6148
NCIT	C4589
SNOMED CT	92663007
UMLS	C0347095
MedGen	138077
Anatomy (UBERON)	UBERON:0001707
Is cancer (heuristic)	yes

Also known as: carcinoma in situ of nasal cavity · carcinoma in situ of the nasal cavity · nasal cavity carcinoma in situ · nasal cavity in situ carcinoma · stage 0 carcinoma of nasal cavity · stage 0 carcinoma of the nasal cavity · stage 0 nasal cavity cancer · stage 0 nasal cavity cancer aJCC v6, v7, and v8 · stage 0 nasal cavity carcinoma · stage 0 nasal cavity carcinoma aJCC v6 · stage 0 nasal cavity carcinoma aJCC v7 · stage 0 nasal cavity carcinoma aJCC v8

Disease family

This is a subtype of nasal cavity carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › nasal cavity cancer › nasal cavity carcinoma › nasal cavity carcinoma in situ

Related subtypes (3): nasal cavity adenocarcinoma, carcinoma arising in nasal papillomatosis, nasal cavity squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.